Knight ADRC Collection

The search for novel risk factors and genetic modifiers for Alzheimer disease relies on the access to accurate and deeply phenotyped datasets. The Memory and Aging Project (MAP) at the Knight-ADRC (Washington University in St. Louis) collects cognitive data, CSF and imaging longitudinally.  This clinical information combined with deep molecular phenotyping (i.e. genetic, proteomics, transcriptomics, metabolomics and lipidomics among others) will lead to the identification of novel genetic modifiers, protective variants, molecular biomarkers and the novel targets. Participants were recruited by the Knight-ADRC at Washington University in St. Louis (MO). Knight-ADRC participants have to be at least 65 years old and have no memory problems or mild dementia at the time of enrollment.

The cohort consists of individuals who are non-Hispanic white from North America (95%) or African American (5%). Individuals carrying known mutations in the Mendelian genes for AD (APP, PSEN1, PSEN2) or Frontotemporal Dementia (GRN, MAPT, C9ORF72) were excluded.  AD definition is based on a combination of both clinical and pathological information if available. Pathologic diagnosis will overrule clinical diagnosis.  Autopsy information is provided if available, but is not a requirement for enrollment.


Dataset Name Type Cases/Controls Total Subjects
NG00030 WashU1 GWAS GWAS
208 / 350 678
NG00035 GWAS of CSF tau levels identifies risk variants for AD


NA 1934
NG00050 GWAS of CLU, A potential endophenotype for Alzheimer's disease GWAS
NA 673
NG00083 Circular RNAs in Alzheimer Disease Brains - RNA-seq Data Summary Statistics/RNA-Seq    
NG00085 ExomeChip - WashU GWAS 519 / 349 868
NG00087 WashU2 GWAS GWAS
38 / 94


NG00089 CSF TREM2 Summary Statistics Summary Statistics NA NA
NG00067 Knight ADRC - WES Whole Exome Sequencing 253/346 650
NG00102 Genomic and multi-tissue proteomic integration for understanding the genetic architecture of neurological diseases Individual-level data (proteomics + array-based genotype data after imputation) and summary statistics CSF- 201/612
Plasma- 167/357
Brain- 234/22
CSF- 817
Plasma- 528
Brain- 343


We thank the contributors who collected samples used in this study, as well as patients and their families, whose help and participation made this work possible. This work was supported by access to equipment made possible by the Hope Center for Neurological Disorders, and the Departments of Neurology and Psychiatry at Washington University School of Medicine.